Prihlásiť sa Zaregistrujte sa zadarmo

Net debt/EBITDA spoločnosti Inhibrx

Aká je hodnota metriky Net debt/EBITDA spoločnosti Inhibrx?

Hodnota metriky Net debt/EBITDA spoločnosti Inhibrx, Inc. je 4.13

Aká je definícia metriky Net debt/EBITDA?



The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.

The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.

Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization

Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.

Net debt/EBITDA spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Inhibrx

Čomu sa venuje spoločnosť Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Firmy s metrikou net debt/ebitda podobnou spoločnosti Inhibrx



  • Hodnota metriky Net debt/EBITDA spoločnosti Unity Biotechnology Inc je 4.12
  • Hodnota metriky Net debt/EBITDA spoločnosti CVR Inc je 4.12
  • Hodnota metriky Net debt/EBITDA spoločnosti Rhythm Pharmaceuticals je 4.13
  • Hodnota metriky Net debt/EBITDA spoločnosti Sego Resources je 4.13
  • Hodnota metriky Net debt/EBITDA spoločnosti Datagroup Se je 4.13
  • Hodnota metriky Net debt/EBITDA spoločnosti DATAGROUP SE je 4.13
  • Hodnota metriky Net debt/EBITDA spoločnosti Inhibrx je 4.13
  • Hodnota metriky Net debt/EBITDA spoločnosti APA je 4.13
  • Hodnota metriky Net debt/EBITDA spoločnosti Formycon AG je 4.13
  • Hodnota metriky Net debt/EBITDA spoločnosti DMC Global Inc je 4.14
  • Hodnota metriky Net debt/EBITDA spoločnosti Elementos je 4.14
  • Hodnota metriky Net debt/EBITDA spoločnosti Lokesh Machines je 4.15
  • Hodnota metriky Net debt/EBITDA spoločnosti Campine NV je 4.15